The novel oral gonadotropin‐releasing hormone receptor antagonist relugolix is a new option for controlled ovarian stimulation cycles
Abstract Purpose Relugolix is an oral gonadotropin‐releasing hormone antagonist (GnRHant), which was first introduced in 2019. This study investigated the effects of the conventional injectable GnRHant formulation and this new oral GnRHant formulation on controlled ovarian stimulation (COS) cycles....
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Reproductive Medicine and Biology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/rmb2.12448 |
| _version_ | 1797976005292326912 |
|---|---|
| author | Shinnosuke Komiya Tomoko Tsuzuki‐Nakao Yoshiko Asai Tomoko Inoue Yoshiharu Morimoto Hidetaka Okada |
| author_facet | Shinnosuke Komiya Tomoko Tsuzuki‐Nakao Yoshiko Asai Tomoko Inoue Yoshiharu Morimoto Hidetaka Okada |
| author_sort | Shinnosuke Komiya |
| collection | DOAJ |
| description | Abstract Purpose Relugolix is an oral gonadotropin‐releasing hormone antagonist (GnRHant), which was first introduced in 2019. This study investigated the effects of the conventional injectable GnRHant formulation and this new oral GnRHant formulation on controlled ovarian stimulation (COS) cycles. Methods Relugolix was administered in 126 cycles and conventional GnRHant injection was administered in 658 cycles (controls). The follicle stimulation was performed by an antagonist method, and for final oocyte maturation, recombinant human chorionic gonadotropin (rHCG), or gonadotropin‐releasing hormone agonist (GnRHa), or both (dual trigger) were selected. The number of retrieved oocytes was counted and then they were evaluated for subsequent development up to cleavage stage. Results The number of retrieved oocytes which was the primary outcome of this research was affected by the combination of GnRHant type and the final oocyte maturation agent. The combination of relugolix and a GnRHa trigger showed a significantly lower number of retrieved oocytes (p < 0.001) than the other combinations. Conclusions Relugolix is a new option for COS cycles, but should be carefully combined with the final maturation agent. Clinical trial approval This study was conducted after approval by the Medical Corporation Sankeikai Institutional Ethics Committee (approval number: 2019‐34). |
| first_indexed | 2024-04-11T04:44:25Z |
| format | Article |
| id | doaj.art-5a86fefd6c8c476d9c9a863cf4984d7b |
| institution | Directory Open Access Journal |
| issn | 1445-5781 1447-0578 |
| language | English |
| last_indexed | 2024-04-11T04:44:25Z |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Reproductive Medicine and Biology |
| spelling | doaj.art-5a86fefd6c8c476d9c9a863cf4984d7b2022-12-27T13:54:58ZengWileyReproductive Medicine and Biology1445-57811447-05782022-01-01211n/an/a10.1002/rmb2.12448The novel oral gonadotropin‐releasing hormone receptor antagonist relugolix is a new option for controlled ovarian stimulation cyclesShinnosuke Komiya0Tomoko Tsuzuki‐Nakao1Yoshiko Asai2Tomoko Inoue3Yoshiharu Morimoto4Hidetaka Okada5Department of Obstetrics and Gynecology Kansai Medical University Graduate School of Medicine Osaka JapanDepartment of Obstetrics and Gynecology Kansai Medical University Graduate School of Medicine Osaka JapanHORAC Grand Front Osaka Clinic Osaka JapanHORAC Grand Front Osaka Clinic Osaka JapanHORAC Grand Front Osaka Clinic Osaka JapanDepartment of Obstetrics and Gynecology Kansai Medical University Graduate School of Medicine Osaka JapanAbstract Purpose Relugolix is an oral gonadotropin‐releasing hormone antagonist (GnRHant), which was first introduced in 2019. This study investigated the effects of the conventional injectable GnRHant formulation and this new oral GnRHant formulation on controlled ovarian stimulation (COS) cycles. Methods Relugolix was administered in 126 cycles and conventional GnRHant injection was administered in 658 cycles (controls). The follicle stimulation was performed by an antagonist method, and for final oocyte maturation, recombinant human chorionic gonadotropin (rHCG), or gonadotropin‐releasing hormone agonist (GnRHa), or both (dual trigger) were selected. The number of retrieved oocytes was counted and then they were evaluated for subsequent development up to cleavage stage. Results The number of retrieved oocytes which was the primary outcome of this research was affected by the combination of GnRHant type and the final oocyte maturation agent. The combination of relugolix and a GnRHa trigger showed a significantly lower number of retrieved oocytes (p < 0.001) than the other combinations. Conclusions Relugolix is a new option for COS cycles, but should be carefully combined with the final maturation agent. Clinical trial approval This study was conducted after approval by the Medical Corporation Sankeikai Institutional Ethics Committee (approval number: 2019‐34).https://doi.org/10.1002/rmb2.12448fertilization in vitroinfertilityoocyte retrievalreproductive techniques, assistedsperm injections, intra‐cytoplasmic |
| spellingShingle | Shinnosuke Komiya Tomoko Tsuzuki‐Nakao Yoshiko Asai Tomoko Inoue Yoshiharu Morimoto Hidetaka Okada The novel oral gonadotropin‐releasing hormone receptor antagonist relugolix is a new option for controlled ovarian stimulation cycles Reproductive Medicine and Biology fertilization in vitro infertility oocyte retrieval reproductive techniques, assisted sperm injections, intra‐cytoplasmic |
| title | The novel oral gonadotropin‐releasing hormone receptor antagonist relugolix is a new option for controlled ovarian stimulation cycles |
| title_full | The novel oral gonadotropin‐releasing hormone receptor antagonist relugolix is a new option for controlled ovarian stimulation cycles |
| title_fullStr | The novel oral gonadotropin‐releasing hormone receptor antagonist relugolix is a new option for controlled ovarian stimulation cycles |
| title_full_unstemmed | The novel oral gonadotropin‐releasing hormone receptor antagonist relugolix is a new option for controlled ovarian stimulation cycles |
| title_short | The novel oral gonadotropin‐releasing hormone receptor antagonist relugolix is a new option for controlled ovarian stimulation cycles |
| title_sort | novel oral gonadotropin releasing hormone receptor antagonist relugolix is a new option for controlled ovarian stimulation cycles |
| topic | fertilization in vitro infertility oocyte retrieval reproductive techniques, assisted sperm injections, intra‐cytoplasmic |
| url | https://doi.org/10.1002/rmb2.12448 |
| work_keys_str_mv | AT shinnosukekomiya thenoveloralgonadotropinreleasinghormonereceptorantagonistrelugolixisanewoptionforcontrolledovarianstimulationcycles AT tomokotsuzukinakao thenoveloralgonadotropinreleasinghormonereceptorantagonistrelugolixisanewoptionforcontrolledovarianstimulationcycles AT yoshikoasai thenoveloralgonadotropinreleasinghormonereceptorantagonistrelugolixisanewoptionforcontrolledovarianstimulationcycles AT tomokoinoue thenoveloralgonadotropinreleasinghormonereceptorantagonistrelugolixisanewoptionforcontrolledovarianstimulationcycles AT yoshiharumorimoto thenoveloralgonadotropinreleasinghormonereceptorantagonistrelugolixisanewoptionforcontrolledovarianstimulationcycles AT hidetakaokada thenoveloralgonadotropinreleasinghormonereceptorantagonistrelugolixisanewoptionforcontrolledovarianstimulationcycles AT shinnosukekomiya noveloralgonadotropinreleasinghormonereceptorantagonistrelugolixisanewoptionforcontrolledovarianstimulationcycles AT tomokotsuzukinakao noveloralgonadotropinreleasinghormonereceptorantagonistrelugolixisanewoptionforcontrolledovarianstimulationcycles AT yoshikoasai noveloralgonadotropinreleasinghormonereceptorantagonistrelugolixisanewoptionforcontrolledovarianstimulationcycles AT tomokoinoue noveloralgonadotropinreleasinghormonereceptorantagonistrelugolixisanewoptionforcontrolledovarianstimulationcycles AT yoshiharumorimoto noveloralgonadotropinreleasinghormonereceptorantagonistrelugolixisanewoptionforcontrolledovarianstimulationcycles AT hidetakaokada noveloralgonadotropinreleasinghormonereceptorantagonistrelugolixisanewoptionforcontrolledovarianstimulationcycles |